UGC Approved Journal no 63975(19)

ISSN: 2349-5162 | ESTD Year : 2014
Call for Paper
Volume 11 | Issue 3 | March 2024

JETIREXPLORE- Search Thousands of research papers



WhatsApp Contact
Click Here

Published in:

Volume 8 Issue 10
October-2021
eISSN: 2349-5162

UGC and ISSN approved 7.95 impact factor UGC Approved Journal no 63975

7.95 impact factor calculated by Google scholar

Unique Identifier

Published Paper ID:
JETIR2110044


Registration ID:
310050

Page Number

a327-a336

Share This Article


Jetir RMS

Title

CURRENT SCENARIO IN ANTICANCER DRUG THERAPY

Abstract

Disease is presently the subsequent driving reason for death internationally and is relied upon to be answerable for around 9.6 million passings in 2018. With a remarkable comprehension of the atomic pathways that drive the turn of events and movement of human diseases, novel focused on treatments have become an energizing new improvement for hostile to malignancy medication. These focused on treatments, otherwise called biologic treatments, have become a significant methodology of clinical therapy, by acting to hinder the development of disease cells by explicitly focusing on atoms needed for cell development and tumorigenesis. Because of their particularity, these new treatments are required to have better adequacy and restricted unfriendly results when contrasted and other treatment choices, including hormonal and cytotoxic treatments. Various advancements are right now under assessment in clinical preliminaries or have been now brought into clinical practice. While nanomedicine is adding to the improvement of biocompatible materials both for demonstrative and remedial purposes, bioengineering of extracellular vesicles and cells got from patients has permitted planning impromptu frameworks and univocal focusing on methodologies. In this audit, we will give a top to bottom investigation of the most creative advances in essential and applied malignancy research.

Key Words

Cancer, tumorigenesis, vesicles, targeted therapy, immunotherapy, gene therapy, thermal ablation, radiomics, pathomics

Cite This Article

"CURRENT SCENARIO IN ANTICANCER DRUG THERAPY", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.8, Issue 10, page no.a327-a336, October-2021, Available :http://www.jetir.org/papers/JETIR2110044.pdf

ISSN


2349-5162 | Impact Factor 7.95 Calculate by Google Scholar

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 7.95 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Cite This Article

"CURRENT SCENARIO IN ANTICANCER DRUG THERAPY", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.8, Issue 10, page no. ppa327-a336, October-2021, Available at : http://www.jetir.org/papers/JETIR2110044.pdf

Publication Details

Published Paper ID: JETIR2110044
Registration ID: 310050
Published In: Volume 8 | Issue 10 | Year October-2021
DOI (Digital Object Identifier):
Page No: a327-a336
Country: Nagpur, Maharashtra, India .
Area: Pharmacy
ISSN Number: 2349-5162
Publisher: IJ Publication


Preview This Article


Downlaod

Click here for Article Preview

Download PDF

Downloads

000572

Print This Page

Current Call For Paper

Jetir RMS